Header graphic for print
The Healthcare Investor Insights on Issues & Trends that Impact Investments in Healthcare & Life Science Businesses

Welsh, Carson, Anderson & Stowe Commits Up to $250 Million in New Cell and Gene Therapy Investing Platform

Posted in Healthcare Services Investing

Welsh, Carson, Anderson & Stowe (WCAS) has announced it is committing up to $250 million to a newly formed platform that will invest in non-therapeutic companies supporting cell and gene therapy.

The platform — named Kiniciti and based in New York — plans to invest in a cross section of cell and gene therapy opportunities across multiple geographies.

WCAS, based in New York, is a private equity firm focused exclusively on the healthcare and technology industries. Founded in 1979, the firm targets growth-oriented companies with an investment strategy that is deal-size agnostic.

We use cookies to enhance your experience of our website. By continuing to use this website, you agree to the use of these cookies. For more information and to learn how you can change your cookie settings, please see our policy.

Agree